Published in Clin Cancer Res on March 03, 2011
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol (2013) 1.59
The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One (2011) 1.19
mTOR pathway in colorectal cancer: an update. Oncotarget (2014) 1.15
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin (2012) 1.15
The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci (2013) 1.09
Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res (2011) 1.07
Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res (2013) 1.07
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer. Front Oncol (2012) 1.05
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer (2012) 1.03
Targeting the RAS oncogene. Expert Opin Ther Targets (2013) 1.02
miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation. Cell Death Dis (2014) 1.02
Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions. Breast Cancer (Auckl) (2014) 0.98
Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy. Autophagy (2015) 0.95
PAK1 mediates resistance to PI3K inhibition in lymphomas. Clin Cancer Res (2013) 0.95
Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer. EPMA J (2013) 0.93
Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma. Sarcoma (2012) 0.90
Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer. ScientificWorldJournal (2014) 0.90
Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. PLoS One (2012) 0.90
p110δ PI3 kinase pathway: emerging roles in cancer. Front Oncol (2013) 0.89
Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther (2012) 0.88
Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity. J Invest Dermatol (2013) 0.86
(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer. Transl Oncol (2013) 0.85
Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat. PLoS One (2014) 0.85
Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives. Cancers (Basel) (2011) 0.85
p70 S6 kinase drives ovarian cancer metastasis through multicellular spheroid-peritoneum interaction and P-cadherin/b1 integrin signaling activation. Oncotarget (2014) 0.85
Screening cell mechanotype by parallel microfiltration. Sci Rep (2015) 0.84
Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2. PLoS One (2013) 0.83
MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity. Br J Cancer (2014) 0.83
PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. J Transl Med (2016) 0.82
Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers. PLoS One (2013) 0.82
Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential. Oncotarget (2015) 0.80
Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways. Int J Nanomedicine (2014) 0.80
High expression of Lewis y antigen and CD44 is correlated with resistance to chemotherapy in epithelial ovarian cancers. PLoS One (2013) 0.79
Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis. Int J Nanomedicine (2016) 0.78
Glial progenitors as targets for transformation in glioma. Adv Cancer Res (2014) 0.78
Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines. Front Endocrinol (Lausanne) (2015) 0.77
BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. Transl Oncol (2016) 0.77
Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. Oncotarget (2016) 0.75
Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget (2017) 0.75
The Role and Application of Sirtuins and mTOR Signaling in the Control of Ovarian Functions. Cells (2016) 0.75
Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol (2016) 0.75
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. Cancer Chemother Pharmacol (2016) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Cancer of the ovary. N Engl J Med (2004) 11.21
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther (2008) 10.35
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer (2006) 7.53
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene (2006) 6.54
PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet (1999) 6.18
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res (2008) 5.82
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med (2004) 4.98
mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (2010) 4.81
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther (2006) 4.09
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene (2005) 3.42
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A (2009) 3.26
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A (2008) 3.13
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene (2004) 2.67
Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene (2000) 2.55
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res (2002) 2.37
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther (2009) 2.31
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res (2008) 2.15
In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res (2000) 2.08
Current management strategies for ovarian cancer. Mayo Clin Proc (2007) 1.94
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol (2001) 1.82
RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res (2007) 1.76
RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res (2007) 1.72
Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene (2006) 1.72
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol (2005) 1.69
Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer (2006) 1.68
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res (2009) 1.64
p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res (2003) 1.62
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood (2010) 1.60
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res (2009) 1.54
NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res (2010) 1.52
Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res (2007) 1.48
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res (2008) 1.43
Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem (2002) 1.41
Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood (2009) 1.40
mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res (2009) 1.39
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res (2009) 1.32
Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology (2006) 1.25
Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer (2005) 1.19
Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer (2000) 1.16
High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy. Eur J Cancer (2009) 1.00
Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken) (2010) 0.95
Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. Mol Cancer Ther (2005) 0.92
Ovarian cancer: an overview of treatment options. Clin J Oncol Nurs (2007) 0.79
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 11.86
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol (2012) 8.74
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature (2006) 7.35
Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52
Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J (2003) 5.78
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell (2003) 5.13
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg (2010) 4.75
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell (2011) 4.41
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis (2002) 4.23
PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet (2007) 4.09
Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res (2008) 3.99
mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell (2009) 3.78
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner. Cell Stem Cell (2011) 3.56
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell (2010) 3.41
Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A (2004) 3.40
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol (2008) 3.36
Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A (2006) 3.34
A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell (2012) 3.26
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst (2004) 3.24
Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell (2005) 3.15
In situ proteolysis for protein crystallization and structure determination. Nat Methods (2007) 3.05
Cutaneous metastases from genitourinary malignancies. Urology (2004) 2.97
PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A (2005) 2.93
The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol (2009) 2.68
PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol (2004) 2.52
Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res (2009) 2.49
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature (2008) 2.47
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res (2012) 2.45
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell (2007) 2.43
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development (2002) 2.42
Increased expression of stem cell markers in malignant melanoma. Mod Pathol (2006) 2.39
PTENless means more. Dev Biol (2004) 2.31
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell (2006) 2.29
Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest (2007) 2.26
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res (2005) 2.22
Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell (2007) 2.14
Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat Med (2006) 2.11
Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem (2008) 2.07
PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A (2009) 2.07
Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol (2003) 2.05
Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res (2007) 2.04
A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci (2006) 2.04
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Hepatocellular carcinoma: stiffness value and ratio to discriminate malignant from benign focal liver lesions. Radiology (2015) 2.03
A detrimental mitochondrial-nuclear interaction causes cytoplasmic male sterility in rice. Nat Genet (2013) 1.92
Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem (2005) 1.89
JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A (2012) 1.88
The genomics of selection in dogs and the parallel evolution between dogs and humans. Nat Commun (2013) 1.86
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
Three-dimensional nanostructured substrates toward efficient capture of circulating tumor cells. Angew Chem Int Ed Engl (2009) 1.86
Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. J Infect Dis (2012) 1.83
Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis. J Neurosci (2009) 1.80
Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J Biol Chem (2003) 1.78
Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J Cell Biol (2005) 1.74
Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep (2013) 1.74
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Laparoscopy versus open distal gastrectomy for advanced gastric cancer: a systematic review and meta-analysis. Surg Laparosc Endosc Percutan Tech (2013) 1.72
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol (2010) 1.71
Photodetectors based on intersubband transitions using III-nitride superlattice structures. J Phys Condens Matter (2009) 1.70
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol (2011) 1.67
PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. Proc Natl Acad Sci U S A (2005) 1.67
mTOR is activated in the majority of malignant melanomas. J Invest Dermatol (2007) 1.66
The role of erythropoietin in regulating angiogenesis. Dev Biol (2004) 1.66
PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res (2010) 1.65
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
Genetic background controls tumor development in PTEN-deficient mice. Cancer Res (2006) 1.63
Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes. Mol Cell Biol (2006) 1.61
Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol Cell Biol (2005) 1.61
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol (2012) 1.60
Protein-based nanomedicine platforms for drug delivery. Small (2009) 1.59
Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res (2008) 1.58
Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol Cell Biol (2002) 1.57
PTEN, stem cells, and cancer stem cells. J Biol Chem (2008) 1.52
Strand transfer events during HIV-1 reverse transcription. Virus Res (2008) 1.51
Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis. J Gastroenterol Hepatol (2009) 1.50
Actinide sequestration using self-assembled monolayers on mesoporous supports. Environ Sci Technol (2005) 1.48
Glucose oxidase-graphene-chitosan modified electrode for direct electrochemistry and glucose sensing. Biosens Bioelectron (2009) 1.46
An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells. Nat Commun (2011) 1.45
The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A (2010) 1.45
Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med (2010) 1.44
Direct electrochemistry and electrocatalysis of horseradish peroxidase immobilized in hybrid organic-inorganic film of chitosan/sol-gel/carbon nanotubes. Talanta (2008) 1.43
BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol (2007) 1.43
Plasma miR-126 as a potential marker predicting major adverse cardiac events in dual antiplatelet-treated patients after percutaneous coronary intervention. EuroIntervention (2013) 1.42
DNA array-based method for detection of large rearrangements in the BRCA1 gene. Genes Chromosomes Cancer (2002) 1.41
Sensitive immunoassays of nitrated fibrinogen in human biofluids. Talanta (2010) 1.40
Quercetin induces protective autophagy in gastric cancer cells: involvement of Akt-mTOR- and hypoxia-induced factor 1α-mediated signaling. Autophagy (2011) 1.40
Erythroid expansion mediated by the Gfi-1B zinc finger protein: role in normal hematopoiesis. Blood (2002) 1.39
Negative regulation of NF-kappaB signaling by PIAS1. Mol Cell Biol (2005) 1.38
PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol Cell Biol (2008) 1.38